David Z. I. Cherney

David Z. I. Cherney

Auto-generated profile, based on publicly available information

David Z. I. Cherney

Division of Nephrology, Department of Medicine, University Health Network, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2016 in Circulation
Verified
Journal Article
Closed access
HHHiddo J.L. Heerspink
Hiddo J.L. Heerspink
BPBruce A. Perkins
Bruce A. Perkins
DFDavid H. Fitchett
David H. Fitchett
MHMansoor Husain
Mansoor Husain
DCDavid Z. I. Cherney
David Z. I. Cherney
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their unique glycosuric mechanism, SGLT2 inhibitors also reduce weight. Perhaps more important are the osmotic diuretic and natriuretic effects contributing to plasma volume contraction, and decreases in systolic and diastolic blood pressures by 4 to 6 and 1 to 2 mm Hg, respectively, which may underlie cardiovascular and kidney benefits. SGLT2 inhibition also is associated with an acute, dose-dependent reduction in estimated glomerular filtration rate by ≈5 mL·min–1·1.73 m–2and ≈30% to 40% reduction in albuminuria. These effects mirror preclinical observations suggesting that proximal tubular natriuresis activates renal tubuloglomerular feedback through increased macula densa sodium and chloride delivery, leading to afferent vasoconstriction. On the basis of reduced glomerular filtration, glycosuric and weight loss effects are attenuated in patients with chronic kidney disease (estimated glomerular filtration rate 30% reductions in cardiovascular mortality, overall mortality, and heart failure hospitalizations associated with empagliflozin, even though, by design, the hemoglobin A1c difference between the randomized groups was marginal. Aside from an increased risk of mycotic genital infections, empagliflozin-treated patients had fewer serious adverse events, including a lower risk of acute kidney injury. In light of the EMPA-REG OUTCOME results, some diabetes clinical practice guidelines now recommend that SGLT2 inhibitors with proven cardiovascular benefit be prioritized in patients with type 2 diabetes mellitus who have not achieved glycemic targets and who have prevalent atherosclerotic cardiovascular disease. With additional cardiorenal protection trials underway, sodium-related physiological effects of SGLT2 inhibitors and clinical correlates of natriuresis, such as the impact on blood pressure, heart failure, kidney protection, and mortality, will be a major management focus.

4 February 2014 in Circulation
Verified
Journal Article
Closed access
DCDavid Z.I. Cherney
David Z.I. Cherney
BPBruce A. Perkins
Bruce A. Perkins
NSNima Soleymanlou
Nima Soleymanlou
MMMaria Maione
Maria Maione
VLVesta Lai
Vesta Lai
MEMaximilian von Eynatten
Maximilian von Eynatten
Background—: The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect of 8 weeks’ sodium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in subjects with type 1 diabetes mellitus (T1D). Methods and Results—: Inulin (glomerular filtration rate; GFR) and paraaminohippurate (effective renal plasma flow) clearances were measured in individuals stratified based on having hyperfiltration (T1D-H, GFR ≥ 135 mL/min/1.73m 2 , n=27) or normal GFR (T1D-N, GFR 90–134 mL/min/1.73m 2 , n=13) at baseline. Renal function and circulating levels of renin-angiotensin-aldosterone system mediators and NO were measured under clamped euglycemic (4–6 mmol/L) and hyperglycemic (9–11 mmol/L) conditions at baseline and end of treatment. During clamped euglycemia, hyperfiltration was attenuated by −33 mL/min/1.73m 2 with empagliflozin in T1D-H, (GFR 172±23–139±25 mL/min/1.73 m 2 , P <0.01). This effect was accompanied by declines in plasma NO and effective renal plasma flow and an increase in renal vascular resistance (all P <0.01). Similar significant effects on GFR and renal function parameters were observed during clamped hyperglycemia. In T1D-N, GFR, other renal function parameters, and plasma NO were not altered by empagliflozin. Empagliflozin reduced hemoglobin A1c significantly in both groups, despite lower insulin doses in each group ( P ≤0.04). Conclusions—: In conclusion, short-term treatment with the sodium glucose cotransporter 2 inhibitor empagliflozin attenuated renal hyperfiltration in subjects with T1D, likely by affecting tubular-glomerular feedback mechanisms. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01392560.

1 January 2014 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
DCDavid Zi Cherney
David Zi Cherney
BPBruce A Perkins
Bruce A Perkins
NSNima Soleymanlou
Nima Soleymanlou
RHRonnie Har
Ronnie Har
NFNora Fagan
Nora Fagan
UBUli C Broedl
Uli C Broedl
Individuals with type 1 diabetes mellitus are at high risk for the development of hypertension, contributing to cardiovascular complications. Hyperglycaemia-mediated neurohormonal activation increases arterial stiffness, and is an important contributing factor for hypertension. Since the sodium glucose cotransport-2 (SGLT2) inhibitor empagliflozin lowers blood pressure and HbA1c in type 1 diabetes mellitus, we hypothesized that this agent would also reduce arterial stiffness and markers of sympathetic nervous system activity.

24 October 2017 in Circulation
Verified
Journal Article
Closed access
PDF file
YLYuliya Lytvyn
Yuliya Lytvyn
PBPetter Bjornstad
Petter Bjornstad
JUJacob A. Udell
Jacob A. Udell
JLJulie A. Lovshin
Julie A. Lovshin
DCDavid Z.I. Cherney
David Z.I. Cherney
Despite current established therapy, heart failure (HF) remains a leading cause of hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to improve the prognosis of patients with HF. The EMPA-REG OUTCOME trial ([Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) demonstrated significant reductions in mortality and HF hospitalization risk in patients with type 2 diabetes mellitus (T2D) and cardiovascular disease with the antihyperglycemic agent, empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor. The CANVAS trial (Canagliflozin Cardiovascular Assessment Study) subsequently reported a reduction in 3-point major adverse cardiovascular events and HF hospitalization risk. Although SGLT2 inhibition may have potential application beyond T2D, including HF, the mechanisms responsible for the cardioprotective effects of SGLT2 inhibitors remain incompletely understood. SGLT2 inhibition promotes natriuresis and osmotic diuresis, leading to plasma volume contraction and reduced preload, and decreases in blood pressure, arterial stiffness, and afterload as well, thereby improving subendocardial blood flow in patients with HF. SGLT2 inhibition is also associated with preservation of renal function. Based on data from mechanistic studies and clinical trials, large clinical trials with SGLT2 inhibitors are now investigating the potential use of SGLT2 inhibition in patients who have HF with and without T2D. Accordingly, in this review, we summarize the key pharmacodynamic effects of SGLT2 inhibitors and the clinical evidence that support the rationale for the use of SGLT2 inhibitors in patients with HF who have T2D. Because these favorable effects presumably occur independent of blood glucose lowering, we also explore the potential use of SGLT2 inhibition in patients without T2D with HF or at risk of HF, such as in patients with coronary artery disease or hypertension. Finally, we provide a detailed overview and summary of ongoing cardiovascular outcome trials with SGLT2 inhibitors.

1 July 2018 in Kidney International
Verified
Journal Article
Closed access
HHHiddo J.L. Heerspink
Hiddo J.L. Heerspink
MKMikhail Kosiborod
Mikhail Kosiborod
SISilvio E. Inzucchi
Silvio E. Inzucchi
DCDavid Z.I. Cherney
David Z.I. Cherney

1 August 2017 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
DCDavid Z I Cherney
David Z I Cherney
BZBernard Zinman
Bernard Zinman
SISilvio E Inzucchi
Silvio E Inzucchi
AKAudrey Koitka-Weber
Audrey Koitka-Weber
MMMichaela Mattheus
Michaela Mattheus
CWChristoph Wanner
Christoph Wanner